Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987–2016
Table 1
Relative survival rates of pancreatic neuroendocrine neoplasm patients during the periods of 1987–1996, 1997–2006, and 2007–2016 at nine SEER sites. Data are represented as mean ± standard error of the mean, with number of patients in parentheses.
Age group
Decade
1987–1996
1997–2006
2007–2016
12-Mo RS
All
73.0 ± 2.1 (474)
73.7 ± 1.6 (833)
82.6 ± 0.9 (2159)
0–44
85.3 ± 3.5 (101)
88.4 ± 2.7 (146)
92.7 ± 1.6 (301)
45–59
83.8 ± 3.1 (149)
82.3 ± 2.2 (303)
85.1 ± 1.4 (706)
60–74
63.8 ± 3.9 (162)
66.7 ± 3.0 (264)
81.2 ± 1.5 (809)
75+
50.3 ± 6.8 (62)
48.7 ± 4.8 (120)
72.0 ± 2.8 (343)
60-Mo RS
All
41.6 ± 2.4 (474)
44.3 ± 1.8 (833)
63.4 ± 1.5 (2159)
0–44
50.0 ± 5.0 (101)
63.1 ± 4.1 (146)
74.5 ± 3.3 (301)
45–59
52.8 ± 4.2 (149)
47.0 ± 3.0 (303)
65.8 ± 2.3 (706)
60–74
34.3 ± 4.1 (162)
40.6 ± 3.3 (264)
62.9 ± 2.4 (809)
75+
16.7 ± 6.0 (62)
20.7 ± 4.5 (120)
48.4 ± 5.0 (343)
120-Mo RS
All
27.5 ± 2.3 (474)
33.6 ± 1.8 (833)
51.1 ± 2.8 (2159)
0–44
31.9 ± 4.8 (101)
52.6 ± 4.3 (146)
65.2 ± 5.2 (301)
45–59
33.8 ± 4.2 (149)
33.4 ± 2.9 (303)
55.9 ± 5.6 (706)
60–74
23.1 ± 4.0 (162)
31.1 ± 3.4 (264)
47.4 ± 4.9 (809)
75+
13.0 ± 7.3 (62)
13.5 ± 4.6 (120)
22.7 ± 9.0 (343)
Abbreviations: Mo, month; RS, relative survival; SEM, standard error of the mean. ,,, for comparisons with the preceding decade.
